Companies › Kailera
2 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 2, 1 Phase 1; Metabolic and endocrine, Genitourinary; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ribupatide (KAI-9531) GLP-1 receptor agonist | GLP1R | Phase 3 | Obesity; Obesity With Diabetes; End Stage Renal Disease | May 2027 |
| KAI-7535 | – | Phase 2 | Obesity | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07458269 | Ribupatide (KAI-9531) | Phase 2 | Obesity | Metabolic and endocrine | May 2027 |
| NCT07497880 | KAI-7535 | Phase 2 | Obesity | Metabolic and endocrine | Jul 2027 |
| NCT07793929 | Ribupatide (KAI-9531) | Phase 1 | End Stage Renal Disease | Genitourinary | Feb 2028 |
| NCT07284875 | Ribupatide (KAI-9531) | Phase 3 | Obesity | Metabolic and endocrine | Feb 2028 |
| NCT07284979 | Ribupatide (KAI-9531) | Phase 3 | Obesity | Metabolic and endocrine | Mar 2028 |
| NCT07284901 | Ribupatide (KAI-9531) | Phase 3 | Obesity With Diabetes | Metabolic and endocrine | Mar 2028 |
Cash and short-term investments of $1.0bn on 2026-09-30; operating cash outflow about $375m a year; runway about 33 months at that burn, to Jul 2029; 5 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Chendu DIAO Pharmaceutical Group Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Beijing QL Biopharmaceutical Hangzhou Sciwind Biosciences Amylyx Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.